Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stocks Crossing The 13 Week Moving Average <$10.01 -- Ignore unavailable to you. Want to Upgrade?

To: Mel Spivak who wrote (2290)	7/21/1998 2:38:00 PM
From: Dennis C	Respond to of 13094

PM may close above $11 today. (Cross the finger) Very interesting thing is they file 10Q before earning released. Believed they have some thing good but don't like to put it into the 10Q. PM is also a hold for longer term. Within this year we shall see a double from its bottom (8 1/2). DC

To: Mel Spivak who wrote (2290)	7/22/1998 5:22:00 PM
From: Dennis C	Respond to of 13094

PM - Polymedica NEW YORK (July 22) BUSINESS WIRE -July 22, 1998--Oscar Gruss & Son Incorporated updates research on PolyMedica Corp., Woburn, MA, and has raised revenue and earnings estimates for the remainder of fiscal 1999. Oscar Gruss & Son maintains a BUY recommendation on the common shares of PolyMedica with a 12-month target price of $15. (AMEX: PM-10 9/16). William Prather R.Ph., M.D., equity analyst at Oscar Gruss & Son, has issued a research broadcast surrounding PolyMedica's fiscal Q1-99 results. On July 21, 1998 PolyMedica Corp. reported both record revenues and earnings of $20.7 million and $0.13 respectively for fiscal Q1-99, exceeding consensus estimates for all analysts who follow the Company. Oscar Gruss & Son has now revised its revenue and earnings per share estimates for fiscal 1999 from $91.9 million and $0.63 to $92.3 million and $0.63 respectively. Beginning on July 1, 1998, Medicare began a new reimbursement program that now covers monitoring supplies for non-insulin-using senior diabetics. Medicare now covers supplies for both insulin-using and non-insulin-using Medicare patients. Dr. Prather believes that PolyMedica has now begun shipping supplies to these patients, potentially tripling this market from approximately 1.2 million to approximately 3.2 million patients in size. Dr. Prather gives details regarding his BUY recommendation for PolyMedica,Corp. in a research report available from Oscar Gruss & Son Incorporated at (212) 514-2343. Investment Ratings: STRONG BUY: expected total annual return of greater than 25% over the next 12-18 months; BUY: expected total annual return in the range of 15-25% over the next 12-18 months; SPECULATIVE BUY: stock for investors who can afford higher risks; expected total annual return of greater than 25% if anticipated contingencies materialize over the next 12 - 18 months with the potential for high return volatility, lower or negative total annual returns in this time period may be possible; HOLD: stock is fairly valued and may provide returns which approximate returns expected from the its peer group in the equity markets over the next 12-18 months, or perhaps less. Other factors considered in the Investment Ratings may include, but are not limited to, the company's risk profile, including earnings predictability, financial position, industry position, technology and product risks, management strengths, and other factors. The required annual return for a specific Investment Rating will be increased for stocks with greater financial, business, and/or earnings risk. This report is based upon information which Oscar Gruss & Son Incorporated believes to be reliable. However, neither Oscar Gruss & Son Incorporated nor any individual acting on its behalf can guarantee the accuracy or completeness of its contents. It does not purport to contain a complete analysis of every material fact concerning any company, industry or security. Oscar Gruss & Son Incorporated assumes that it will be read in conjunction with other available reports and data. Opinions expressed herein are subject to change without notice. No investor can assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Oscar Gruss & Son Incorporated and/or its employees and affiliates may have positions in securities which are referred to herein and may make purchases or sales thereof while this report is in circulation. Further information is available upon request. Foreign-currency-denominated securities are subject to fluctuations in currency exchange rates that could have a positive or adverse effect on an investor's return upon the conversion into local currency of dividends or interest received, or proceeds from the sale of such securities. In addition, the value of U.S. dollar-denominated ADRs and the value of U.S. dollar-denominated ordinary shares, or common shares, of foreign issuers can be influenced by fluctuations in currency exchange rates. -0- sdg/ny* CONTACT: Oscar Gruss & Son Incorporated, New York